Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19209056 | STABLE PHARMACEUTICAL FORMULATIONS OF AMINO ACIDS, PEPTIDES OR PROTEINS | May 2025 | January 2026 | Allow | 8 | 1 | 0 | Yes | No |
| 18777142 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | July 2024 | February 2026 | Abandon | 19 | 0 | 1 | No | No |
| 18736363 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | June 2024 | April 2025 | Allow | 10 | 1 | 0 | No | No |
| 18655571 | 4,4'-[(2-HYDROXYPROPANE-1,3-DIYL)BIS(OXY)]DIBENZALDEHYDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | May 2024 | October 2024 | Allow | 6 | 0 | 1 | No | No |
| 18651753 | PEST CONTROL SPRAY | May 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18633053 | Toothpaste for Delivery of Allergens to Oral Mucosa | April 2024 | August 2025 | Allow | 16 | 1 | 0 | No | No |
| 18419590 | METHOD FOR SUPPORTING MEMORY FUNCTION AND/OR COGNITIVE FUNCTION | January 2024 | December 2024 | Allow | 11 | 1 | 0 | No | No |
| 18416302 | COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR TREATING OCULAR DISEASES WITH ABNORMAL NEOVASCULARIZATION | January 2024 | September 2025 | Allow | 20 | 1 | 1 | No | No |
| 18410212 | Pharmaceutical Formulation | January 2024 | November 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18400079 | 4,4'-[(2-HYDROXYPROPANE-1,3-DIYL)BIS(OXY)]DIBENZALDEHYDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | December 2023 | November 2024 | Abandon | 10 | 1 | 1 | No | No |
| 18390158 | LEAVE-ON ORAL CARE COMPOSITIONS | December 2023 | May 2025 | Allow | 17 | 2 | 0 | No | No |
| 18516466 | INFUSION DOSAGE FORM OF NOREPINEPHRINE | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18514738 | HYPERBRANCHED POLYGLYCEROL-COATED PARTICLES AND METHODS OF MAKING AND USING THEREOF | November 2023 | October 2024 | Allow | 11 | 1 | 0 | No | No |
| 18506633 | FULVESTRANT FORMULATIONS | November 2023 | December 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18498485 | Dentifrice Compositions Comprising Tin Ions | October 2023 | March 2025 | Allow | 16 | 2 | 0 | No | No |
| 18498468 | Oral Care Compositions Comprising Tin Ions | October 2023 | March 2025 | Allow | 16 | 2 | 0 | No | No |
| 18485516 | Methods and Compositions for Treating Diabetes | October 2023 | February 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18378498 | SOLID COMPOSITION | October 2023 | March 2026 | Allow | 29 | 2 | 0 | No | No |
| 18370372 | COMPOSITIONS FOR REDUCTION OF OXIDATIVE STRESS, IMPROVEMENT TO THE IMMUNE SYSTEM, PROMOTION OF HEALTHY CARTILAGE AND/OR ALLEVIATION OF PAIN ACCOMPANYING INFLAMMATORY DISEASES IN RUMINANTS | September 2023 | October 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18244377 | ANTIMICROBIAL COMPOSITIONS | September 2023 | March 2025 | Allow | 18 | 2 | 0 | No | No |
| 18239617 | 1,3-BIS(NAPHTHALEN-2-YLOXY)PROPAN-2-ONE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | August 2023 | November 2023 | Allow | 3 | 0 | 0 | No | No |
| 18275739 | ANTIMICROBIAL COMPOSITE FILM AND METHOD FOR MAKING THE SAME | August 2023 | March 2026 | Abandon | 31 | 1 | 0 | No | No |
| 18224348 | ANTIMICROBIAL COMPOSITIONS INCLUDING COPPER(I) SALTS AND ADDITIVES | July 2023 | April 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18340177 | TOPICAL ANTIVIRAL COMPOSITIONS, DELIVERY SYSTEMS, AND METHODS OF USING THE SAME | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | Yes |
| 18267632 | PESTICIDE COMPOSITIONS OF LICOCHALCONE C | June 2023 | February 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18267620 | PESTICIDE COMPOSITIONS OF PHENOL AND RESORCINOL DIENES AND TRIENES | June 2023 | February 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18335476 | COMPOSITION AND METHOD FOR ATTRACTING VESPID WASPS | June 2023 | February 2026 | Abandon | 32 | 1 | 0 | No | No |
| 18210514 | NON-THERAPEUTIC METHODS FOR ALLEVIATING OR REDUCING STRESS SYMPTOMS OF RUMINANTS | June 2023 | April 2025 | Allow | 22 | 2 | 0 | No | No |
| 18209168 | Intra-Oral Nanoemulsion Including Monolayer Surfactant Bound Particles for Balancing Histamine Response | June 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18207222 | Feral Hog Toxicant | June 2023 | February 2024 | Allow | 8 | 0 | 0 | No | No |
| 18205995 | DELIVERY SYSTEM | June 2023 | April 2025 | Allow | 23 | 2 | 0 | Yes | Yes |
| 18323864 | NATURAL TOOTH POWDER TABLETS | May 2023 | July 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18308260 | INTRANASAL AND TRANSDERMAL ADMINISTRATION OF KAPPA-OPIOID-RECEPTOR AGONISTS: SALVINORIN A FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | April 2023 | August 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18136808 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | April 2023 | May 2024 | Allow | 13 | 1 | 0 | No | No |
| 18136298 | Liposomal Compounds and Methods of Use Thereof | April 2023 | January 2024 | Allow | 9 | 1 | 0 | No | No |
| 18136306 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | April 2023 | July 2024 | Allow | 15 | 2 | 0 | No | No |
| 18247930 | FUNGICIDAL COMPOSITIONS | April 2023 | March 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18194540 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | March 2023 | March 2024 | Allow | 12 | 2 | 0 | No | No |
| 18193328 | PHARMACEUTICAL PREPARATION OF CARBOHYDRATES FOR THERAPEUTIC USE | March 2023 | July 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18247028 | ANTIMICROBIAL AND ANTIVIRAL TREATMENTS OF MATERIALS | March 2023 | December 2025 | Abandon | 33 | 0 | 1 | No | No |
| 18124897 | STABILIZED MENTHOL AND OTHER VOLATILE COMPOUND COMPOSITIONS AND METHODS | March 2023 | February 2024 | Allow | 11 | 1 | 0 | No | No |
| 18025898 | METHOD AND PROCESS FOR COMPLETE ELIMINATION OF VARIOUS STEPS OF PEST GROWTH IN PLANTS USING DISINFECTANT COMPOUNDS BASED ON ETHANEPEROXOIC ACID AND HYDROGEN PEROXIDE | March 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18110654 | LIPID COMPOSITIONS | February 2023 | February 2024 | Allow | 12 | 1 | 0 | No | No |
| 18110791 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | February 2023 | November 2024 | Abandon | 21 | 2 | 0 | No | No |
| 18110373 | BONE GRAFT COMPOSITION AND PREPARATION METHOD THEREFOR | February 2023 | July 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18161988 | DRY POWDER FORMULATIONS FOR INHALATION | January 2023 | March 2025 | Allow | 25 | 4 | 0 | No | No |
| 18158583 | PESTICIDAL OR REPELLANT COMPOSITION AND METHOD OF USE | January 2023 | April 2024 | Abandon | 15 | 3 | 0 | Yes | No |
| 18003579 | USE OF TRIFLUENFURONATE FOR PREVENTION AND TREATMENT OF AGRICULTURAL PEST INSECTS AND MITES | December 2022 | December 2025 | Allow | 35 | 1 | 1 | No | No |
| 18012095 | Synergistic Compositions for the Control of Mosquito-Borne Diseases | December 2022 | December 2025 | Abandon | 36 | 0 | 1 | No | No |
| 18011581 | DISINFECTANT COMPOSITION | December 2022 | December 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 18080474 | TRACE ELEMENT SOLUTION | December 2022 | September 2024 | Abandon | 21 | 2 | 0 | No | No |
| 18076264 | Acetaminophen-Pregabalin Combinations And Methods Of Treating Pain | December 2022 | December 2023 | Allow | 12 | 1 | 0 | No | No |
| 17992481 | INHALABLE LIPOSOMAL SUSTAINED RELEASE COMPOSITION FOR USE IN TREATING PULMONARY DISEASES | November 2022 | October 2025 | Allow | 35 | 2 | 0 | No | No |
| 17962582 | COMPOSITIONS AND METHODS FOR REGULATING THE ENDOCANNABINOID SYSTEM | October 2022 | August 2023 | Allow | 10 | 1 | 0 | No | No |
| 17930931 | SUSTAINED RELEASE OF ANTIINFECTIVES | September 2022 | February 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17823044 | NANO-ENABLED IMMUNOTHERAPY IN CANCER | August 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17819726 | FULVESTRANT FORMULATIONS | August 2022 | November 2023 | Abandon | 15 | 1 | 0 | No | No |
| 17798555 | MULTIPURPOSE ORGANIC ACTIVE BASED ON SOYBEAN OIL AND CAFFEINE | August 2022 | August 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17863885 | LIPID CONTAINING FORMULATIONS | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17852486 | METHODS AND COMPOSITIONS FOR TREATING DIABETES | June 2022 | October 2023 | Abandon | 16 | 1 | 0 | No | No |
| 17789928 | BLADDER, URETER, KIDNEY, URETHRA, PROSTATE AND CATHETER ANTI-MICROBIAL, AND BIOFILM PREVENTION, REDUCTION AND TREATMENT | June 2022 | February 2026 | Allow | 44 | 2 | 0 | Yes | No |
| 17785110 | PINK BOLLWORM CONTROL METHOD | June 2022 | March 2025 | Allow | 33 | 1 | 0 | No | No |
| 17840332 | DIETARY NUTRIENT COMPOSITIONS | June 2022 | June 2024 | Allow | 24 | 3 | 0 | Yes | No |
| 17781871 | IMPROVEMENTS IN WEIGHT CONTROL | June 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17825581 | Formulations of Magnesium Chloride to Treat Muscle Spasm, Strain and Sprain | May 2022 | April 2025 | Allow | 35 | 1 | 0 | No | No |
| 17749657 | METHODS FOR AMELIORATING INFUSION REACTIONS | May 2022 | November 2023 | Allow | 18 | 1 | 0 | No | No |
| 17663586 | Novel 2,4-Dinitrophenol Formulations and Methods Using Same | May 2022 | September 2023 | Allow | 16 | 1 | 0 | No | No |
| 17744275 | MATERIAL FOR DEMINERALIZING DENTIN COLLAGEN FIBRIL, PREPARATION METHOD AND APPLICATION THEREOF | May 2022 | January 2024 | Allow | 20 | 3 | 0 | No | No |
| 17662068 | TREATMENT OF ARDS AND OTHER CONDITIONS CAUSED BY ACUTELY ELEVATED CYTOKINE LEVELS AND POST ARDS CHRONIC CYTOKINE PRODUCTION USING INHALED ANESTHETICS | May 2022 | February 2026 | Allow | 46 | 2 | 0 | No | No |
| 17724019 | ORAL COMPOSITIONS AND METHODS OF USE | April 2022 | March 2024 | Allow | 23 | 2 | 0 | No | No |
| 17715634 | DIETARY NUTRIENT COMPOSITIONS | April 2022 | February 2024 | Abandon | 23 | 4 | 0 | No | No |
| 17715236 | STERICALLY STABILIZED CARRIER FOR AEROSOL THERAPEUTICS, COMPOSITIONS AND METHODS FOR TREATING THE RESPIRATORY TRACT OF A MAMMAL | April 2022 | September 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17712138 | ANTIMICROBIAL COMPOSITION AND SYSTEM FOR DELIVERING AN ANTIMICROBIAL COMPOSITION | April 2022 | August 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17685803 | Antimicrobial Compositions and Uses Thereof | March 2022 | March 2023 | Allow | 13 | 2 | 1 | No | No |
| 17682204 | ORAL CARE COMPOSITION AND DEVICES FORMED THEREWITH | February 2022 | March 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17678512 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | February 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17635644 | A TOPICAL ANTIBIOTIC CONTAINING PHARMACEUTICAL COMPOSITION FOR BACTERIAL INFECTIONS AND WOUND HEALING | February 2022 | December 2025 | Allow | 46 | 2 | 0 | No | No |
| 17633377 | TRANSMISSION PREVENTION OF VIRUSES WITH APPLICATION OF ANTISEPTIC COMPOSITION | February 2022 | August 2025 | Allow | 42 | 2 | 0 | No | No |
| 17630863 | PROCESS FOR MAKING PIROCTONE OLAMINE GRANULES | January 2022 | October 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17584661 | Liver Activation Nanoemulsion and Toxin Excretion Enhancement Method | January 2022 | July 2024 | Allow | 30 | 2 | 0 | No | No |
| 17580224 | Oral Care Product and Methods of Use and Manufacture Thereof | January 2022 | January 2025 | Allow | 36 | 4 | 0 | No | No |
| 17575489 | SUBLINGUAL EPINEPHRINE TABLETS | January 2022 | March 2024 | Allow | 26 | 2 | 0 | No | No |
| 17570635 | VACCINE ADJUVANT FORMULATION | January 2022 | July 2023 | Allow | 18 | 1 | 0 | No | No |
| 17570928 | COMPOSITIONS AND METHODS OF USING NINTEDANIB FOR TREATING OCULAR DISEASES WITH ABNORMAL NEOVASCULARIZATION | January 2022 | October 2023 | Allow | 21 | 1 | 0 | No | No |
| 17566977 | Antimicrobial Products Containing Silver and Copper Particles | December 2021 | August 2024 | Allow | 32 | 2 | 0 | No | No |
| 17618358 | ACID TYPE SOPHOROLIPID-CONTAINING COMPOSITION WHICH IS SUPPRESSED IN BROWNING | December 2021 | December 2025 | Allow | 48 | 1 | 1 | No | No |
| 17457460 | Pharmaceutical Formulation | December 2021 | October 2023 | Allow | 23 | 1 | 0 | No | No |
| 17528844 | Dimethyl Fumarate and Vaccination Regimens | November 2021 | May 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17611283 | METHODS OF TREATING GASTROINTESTINAL CANCERS AND TUMORS THEREOF USING COMBINATION THERAPY | November 2021 | July 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17610329 | HAIR TREATMENT METHOD | November 2021 | July 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17609119 | SUBSTANTIALLY SILICONE-FREE GELLED COMPOSITIONS | November 2021 | February 2026 | Abandon | 51 | 2 | 0 | No | No |
| 17451292 | INFUSION DOSAGE FORM OF NOREPINEPHRINE | October 2021 | September 2023 | Allow | 22 | 2 | 0 | No | No |
| 17497810 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | October 2021 | March 2023 | Allow | 17 | 1 | 0 | No | No |
| 17448012 | REDUCED MISTING PERACID BASED CLEANING, SANITIZING, AND DISINFECTING COMPOSITIONS VIA THE USE OF HIGH MOLECULAR WEIGHT POLYMERS | September 2021 | September 2025 | Allow | 48 | 4 | 0 | Yes | No |
| 17472241 | Oral Care Compositions | September 2021 | February 2025 | Allow | 42 | 5 | 0 | No | No |
| 17433386 | DOSAGE PROJECTILE AND METHOD OF MANUFACTURE | August 2021 | June 2025 | Allow | 45 | 1 | 1 | No | No |
| 17410095 | ANTIVIRAL SMARTPHONE COVER | August 2021 | December 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17408803 | Dentifrice Compositions Comprising Tin Ions | August 2021 | July 2023 | Allow | 23 | 2 | 0 | No | No |
| 17408839 | Oral Care Compositions Comprising Tin Ions | August 2021 | March 2025 | Allow | 42 | 2 | 0 | No | No |
| 17408782 | Oral Care Compositions Comprising Tin Ions | August 2021 | July 2023 | Allow | 23 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MAEWALL, SNIGDHA.
With a 44.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 27.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MAEWALL, SNIGDHA works in Art Unit 1612 and has examined 1,074 patent applications in our dataset. With an allowance rate of 54.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner MAEWALL, SNIGDHA's allowance rate of 54.7% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MAEWALL, SNIGDHA receive 2.39 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MAEWALL, SNIGDHA is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +6.0% benefit to allowance rate for applications examined by MAEWALL, SNIGDHA. This interview benefit is in the 33% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 21.2% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 38.2% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 109.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 79% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 71.8% of appeals filed. This is in the 60% percentile among all examiners. Of these withdrawals, 59.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 72.6% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.7% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.3% of allowed cases (in the 53% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.